All In Biotech

Drug Trial Radar · NCT06553248

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of GZR4 in Chinese Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 22, 2023

Primary completion

Nov 1, 2023

Study completion Nov 1, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes

Conditions

  • Diabetes

Interventions

  • GZR4Drug

    Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks

  • Insulin DegludecDrug

    Administered once daily subcutaneously (s.c., under the skin) for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAETime frame: Baseline to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals Co., Ltd

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.